Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE: Reduced Frequency Immunotherapy in Cancers
NCT04913025Phase 2Unknown
- Sponsor
- University College London
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and pembrolizumab in renal cell carcinoma (RCC) and melanoma (2 arms), sponsored by University College London. Primary endpoint: Progression Free Survival. Status: unknown.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT04913025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04913025.